<DOC>
	<DOCNO>NCT01218594</DOCNO>
	<brief_summary>To evaluate efficacy safety Endostar combine concurrent chemo-radiotherapy ( CCRT ) patient unresectable stage III non-small-cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Curative Effect Study Endostatin Combined With Chemoradiotherapy Non-small-cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary : To assess treatment response rate ( RR ) Endostar combination CCRT Secondary - The progression-free survival ( PFS ) - The overall survival ( OS ) . - The failed treatment modality . - The toxicity regimen . OUTLINE CCRT : Patients receive chemotherapy comprise Docetaxel ( 65mg/m2 , iv gtt duration &gt; 1h ) Cisplatin ( 65mg/m2 , concurrent hydration ) day 1 29 least 3 hour chemotherapy undergo concurrent 3D-CRT five day week total dose 60-66Gy . Endostatin : Patients receive Endostatin 7.5mg/m2 daily iv gtt 7 day consecutively 1 week radiotherapy repeat every 2 week . Patients see follow-up every 3 month 2 year every 6 month thereafter . Physical examination CT scan thorax upper abdomen perform routinely .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>18 year age untreated pathologically confirm inoperable stage IIIA IIIB NSCLC weight loss le 10 % past 6 month performance status ( PS ) 0 1 forced vital capacity 1 second ( FEV1 ) high 0.8 L measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) . absolute neutrophil count ( ANC ) ≥ 1500/μL hemoglobin ≥ 10 mg/dL platelet ≥ 100,000/μL serum creatinine ≤ 1.25 time upper limit normal ( ULN ) calculate creatinine clearance ( CrCl ) ≥ 60 ml/min bilirubin 1.5×ULN AST ALT le 2.5×ULN alkaline phosphatase less 5×ULN . active infection history significant cardiac disease ( unstable angina , congestive heart failure , myocardial infarction within previous 6 month , ventricular arrhythmia ) malnutrition ( loss ≥ 20 % original body weight ) sensor motor neuropathy &gt; grade I second primary malignancy , except nonmelanoma skin cancer psychiatric illness social situation would preclude study compliance pregnant lactate woman preexist bleeding diatheses coagulopathy Prior chemotherapy , chest irradiation therapy , therapy direct epidermal growth factor receptor pathway</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Stage III</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>